Ocugen (OCGN) reported second-quarter 2026 financial results and business updates, including FDA clearance to initiate a Phase 3 trial of OCU410 for geographic atrophy and RMAT designation for the program.
The company reported total revenue of $1.5 million and a net loss of $24.9 million for the three months ended June 30, 2026. Ocugen said it closed a $130.0 million convertible senior notes financing, extending its cash runway into 2028.
- Cash, cash equivalents and restricted cash totaled $100.4 million as of June 30, 2026.
- Net loss per share attributable to common shareholders was $0.07, basic and diluted, for the quarter.
- OCU410 Phase 3 initiation remains on track for the current quarter, with BLA and MAA filings targeted for 2028.
- Topline results are expected for OCU400 in retinitis pigmentosa in the first quarter of 2027 and for OCU410ST in Stargardt disease in the second quarter of 2027.
- Ocugen signed a binding term sheet with Roots Pharmaceutical for a potential exclusive OCU400 license in the MENA region.
$OCGN Insider Trading Activity
$OCGN insiders have traded $OCGN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $OCGN stock by insiders over the last 6 months:
- TREERITA ESSALIMA JOHNSON-GREENE (Chief Financial Officer) purchased 21,000 shares for an estimated $25,830
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OCGN Hedge Fund Activity
We have seen 86 institutional investors add shares of $OCGN stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 8,330,775 shares (+154.4%) to their portfolio in Q1 2026, for an estimated $15,078,702
- RTW INVESTMENTS, LP added 6,666,666 shares (+inf%) to their portfolio in Q1 2026, for an estimated $12,066,665
- STATE STREET CORP added 5,691,453 shares (+143.0%) to their portfolio in Q1 2026, for an estimated $10,301,529
- MARSHALL WACE, LLP added 5,521,394 shares (+218.2%) to their portfolio in Q1 2026, for an estimated $9,993,723
- IKARIAN CAPITAL, LLC added 3,962,972 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,172,979
- QUBE RESEARCH & TECHNOLOGIES LTD added 3,773,066 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,829,249
- GMT CAPITAL CORP added 3,505,398 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,344,770
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
